Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Relationship of Dapagliflozin With Serum Sodium
Su Ern Yeoh, Kieran F. Docherty, Pardeep S. Jhund, et al.
JACC Heart Failure (2022) Vol. 10, Iss. 5, pp. 306-318
Open Access | Times Cited: 22

Showing 22 citing articles:

Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 49
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Evaluation and Management of Hyponatremia in Heart Failure
G.M. Mondellini, Frederik H. Verbrugge
Current Heart Failure Reports (2024) Vol. 21, Iss. 3, pp. 252-261
Closed Access | Times Cited: 6
Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor
Sophie Monnerat, Cihan Atila, Julie Refardt, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 12
HYPONATREMIA IN ACUTE MYOCARDIAL INFARCTION AND SHORT-TERM CLINICAL OUTCOME: A CROSS-SECTIONAL STUDY
N. G., C. Anandi, M Seenivasan
Asian Journal of Pharmaceutical and Clinical Research (2025), pp. 16-19
Open Access
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Reza Amani‐Beni, Bahar Darouei, Davood Shafie, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE
Milton Packer, Javed Butler
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1537-1543
Open Access | Times Cited: 8
Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons
Yuan Gao, Xin Liu, Yunyi Gao, et al.
Gut and Liver (2024) Vol. 18, Iss. 6, pp. 934-948
Open Access | Times Cited: 2
Diabetic Ketoacidosis Management: Updates and Challenges for Specific Patient Population
Azza B. El‐Remessy
Endocrines (2022) Vol. 3, Iss. 4, pp. 801-812
Open Access | Times Cited: 11
A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date
Hui Tang, Changjing Xu, Piao Zhang, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 184, pp. 106415-106415
Open Access | Times Cited: 6
Empagliflozin: a wonder drug for the treatment of SIAD?
Ploutarchos Tzoulis
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium–glucose cotransporter‐2 inhibitor therapy: A multicentre database analysis in Taiwan
Yu‐Wen Cheng, Yi‐Hsin Chan, Chi‐Cheng Chuang, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Chronic heart failure with reduced EF: A decade of major pharmacological innovations
Jean‐Noël Trochu
La Presse Médicale (2023) Vol. 53, Iss. 1, pp. 104219-104219
Closed Access | Times Cited: 2
SGLT-2 inibitori nel trattamento dell’iponatremia. Quale ruolo?
Benedetta Fibbi, Dario Norello
L Endocrinologo (2024) Vol. 25, Iss. 2, pp. 145-150
Open Access
The impact of renal tubulointerstitial dysfunction on the early and long-term prognosis in chronic heart failure patients with preserved left ventricular ejection fraction
В. В. Сыволап, В. А. Лысенко, M. O. Svitlyi
Pathologia (2024) Vol. 21, Iss. 1, pp. 5-13
Open Access
How much salt should i recommend to a patient with CKD: the real mechanisms of regulation of sodium metabolism in kidney pathology
Д.Д. Іванов
Nephrology (Saint-Petersburg) (2024) Vol. 28, Iss. 3, pp. 62-70
Closed Access
Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study
Mohamed Fathy Bakosh, Ramy Mohamed Ghazy, Walid Ismail Ellakany, et al.
Egyptian Liver Journal (2024) Vol. 14, Iss. 1
Open Access
I farmaci SGLT-2 inibitori: utilizzi nella pratica clinica oltre il diabete
Emanuele Varaldo, Alessandro Maria Berton, Daniela Cuboni, et al.
L Endocrinologo (2024)
Closed Access
Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
Ivana Jurin, Vanja Ivanović, Zrinka Šakić, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 11, pp. 364-364
Open Access
From Climatic Resilience to Vulnerability
Simon Stewart
Sustainable development goals series (2024), pp. 53-71
Open Access
A STUDY ON THE PREVALENCE OF ADVERSE EFFECTS ASSOCIATED WITH SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR DAPAGLIFLOZIN IN A TERTIARY CARE CENTRE
S Aswini, Babu Ezhumalai, V. Hanusha, et al.
Asian Journal of Pharmaceutical and Clinical Research (2024), pp. 147-150
Open Access
Update Diuretika
Walter Zidek
CardioVasc (2023) Vol. 23, Iss. 1, pp. 36-39
Closed Access
Page 1

Scroll to top